<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04547153</url>
  </required_header>
  <id_info>
    <org_study_id>SAHMO2-X</org_study_id>
    <nct_id>NCT04547153</nct_id>
  </id_info>
  <brief_title>LD-FUD for Highly Aggressive Gastric Cancer</brief_title>
  <official_title>A Phase II Trial of Low Dose 5-fluorouracil and Dose-dense Docetaxel as First-line Treatment for a Special Type of Highly Aggressive Gastric Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sixth Affiliated Hospital, Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sixth Affiliated Hospital, Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A subtype of gastric adenocarcinoma with extensive bone marrow metastasis and DIC has been&#xD;
      described. Few patients have been treated properly due to the lack of clinical trials. We&#xD;
      designed this phase II study to explore a feasible regimen for this kind of highly aggressive&#xD;
      gastric cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      5-fluorouracil 200mg/m2/day continuously for 20 days; Docetaxel 25mg/m2, days 1, 8 and 15;&#xD;
      This regimen repeats every 4 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hematological response rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percentage of participants whose platelet restored to normal range</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>From date of treatment until the date of death of any cause of the articipants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>2 year</time_frame>
    <description>From date of treatment until the date of disease progression of the participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life assessed by EORTC QOL C-30</measure>
    <time_frame>2 years</time_frame>
    <description>The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (QOL) C-30 questionaire is a general patient self-evaluation of subjective quality life status. The score of this questionnaire ranges between 0 and 30. The higher score indicates the worse quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to hematological response</measure>
    <time_frame>8 weeks</time_frame>
    <description>The interval from treatment to hematological response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percentage of participants with confirmed complete response or partial response determined by Response Evaluation Criteria in Solid Tumors (RECIST)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Bone Marrow Metastasis</condition>
  <condition>Disseminated Intravascular Coagulation</condition>
  <arm_group>
    <arm_group_label>LD-FUD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5-Fu 200mg/m2/day continuously for 20 days; Docetaxel 25mg/m2, days 1, 8 and 15; Repeated every four weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil</intervention_name>
    <description>low dose</description>
    <arm_group_label>LD-FUD</arm_group_label>
    <other_name>5-Fu</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>dose-sense</description>
    <arm_group_label>LD-FUD</arm_group_label>
    <other_name>Doce</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically confirmed gastric adenocarcinoma;&#xD;
&#xD;
          -  Bone marrow metastasis confirmed by aspiration, biopsy or PET/CT scan;&#xD;
&#xD;
          -  DIC;&#xD;
&#xD;
          -  Sufficient liver and renal functions;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  treated by cytotoxic or target or I-O drugs;&#xD;
&#xD;
          -  insufficient cardiac or pulmonary function;&#xD;
&#xD;
          -  active infection;&#xD;
&#xD;
          -  no contraceptive measures;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jian Xiao, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sixth Affiliated Hospital of Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaohui Zhai, MD</last_name>
    <phone>862038285497</phone>
    <phone_ext>862038285497</phone_ext>
    <email>zhaixh@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shanshan Li, MD</last_name>
    <phone>862038285497</phone>
    <phone_ext>862038285497</phone_ext>
    <email>lishsh89@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jian Xiao</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510655</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian Xiao, MD</last_name>
      <phone>862038285497</phone>
      <phone_ext>862038285497</phone_ext>
      <email>xiaoj26@mail.sysu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Morita R, Ishikawa T, Sawai Y, Kajiwara M, Asaeda K, Kobayashi R, Miyazaki H, Doi T, Inoue K, Dohi O, Yoshida N, Kamada K, Uchiyama K, Takagi T, Konishi H, Naito Y, Itoh Y. [A Long-Term Survival Case of Gastric Cancer with Disseminated Intravascular Coagulation due to Myelocarcinomatosis Treated with S-1 plus Oxaliplatin Therapy]. Gan To Kagaku Ryoho. 2021 May;48(5):731-734. Japanese.</citation>
    <PMID>34006725</PMID>
  </reference>
  <reference>
    <citation>Kwon JY, Yun J, Kim HJ, Kim KH, Kim SH, Lee SC, Kim HJ, Bae SB, Kim CK, Lee NS, Lee KT, Park SK, Won JH, Hong DS, Park HS. Clinical outcome of gastric cancer patients with bone marrow metastases. Cancer Res Treat. 2011 Dec;43(4):244-9. doi: 10.4143/crt.2011.43.4.244. Epub 2011 Dec 27.</citation>
    <PMID>22247710</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 7, 2020</study_first_submitted>
  <study_first_submitted_qc>September 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2020</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sixth Affiliated Hospital, Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Jian Xiao</investigator_full_name>
    <investigator_title>Asso Professor</investigator_title>
  </responsible_party>
  <keyword>5-fluorouracil</keyword>
  <keyword>docetaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Disseminated Intravascular Coagulation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>SAP &amp; CSR</ipd_description>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Oct 2022 - Sep 2027</ipd_time_frame>
    <ipd_access_criteria>Researchers interested in the same disease</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

